Pharma's Richest Ride Demand Tailwinds
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
dr reddys laboratories
September 2023
July 2023
April 2023
July 2022
May 2022
December 2021
February 2020
Dr. Reddy's Q1 profit surges 18% to ₹1,403 cr
The revenue witnessed 29% growth at ₹6,738.4 crore in the Q1 of FY24, against ₹5,215.4 crore YoY, driven by sales in North America, emerging markets and Europe.
Dr. Reddy's shares hit 52-week high as USFDA completes inspection of API plant
The pharma major received “zero observations” post the USFDA pre-approval inspection (PAI) and a routine GMP inspection at the Andhra Pradesh facility
Pharma’s R&D Ambitions Go Global
India’s life sciences R&D is undergoing a sea change. Given the huge risks and investments involved, can India taste success in innovative medicine, therapy and diagnostic tools?
Dr. Reddy’s Labs drops 5% despite 1,257% sequential growth in Q1 profit; here's why
Dr. Reddy's posted a consolidated net profit of ₹1,187.6 crore in Q1FY23, registering a yearly growth of 108.05% and 1,257.25% on a quarterly basis.
Torrent Pharma acquires 4 brands from Dr Reddy’s Lab
Torrent Pharma will acquire Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr Reddy’s Laboratories.
Dr Reddy's Q4 net profit tumbles 76%
Revenue of the pharma company rose 15% year-on-year to ₹5,437 crore in the fourth quarter.
IT, pvt banks propel Sensex, Nifty 0.5% higher; HP Adhesives surges 22% on debut
The BSE Sensex ended 296 points higher at 57,420, and the NSE Nifty surged 82.5 points, led by Tech Mahindra, Dr. Reddy's, Power Grid, and Sun Pharma.
55 Indian pharma cos capable of mRNA vaccines
Almost every major Indian pharmaceutical company, including Cipla, Dr Reddy’s, Sun Pharma and Biocon, are on the list of companies which can produce mRNA Covid-19 vaccines
Cipla: Breath of new air
Structural changes in the global pharma industry are throwing up challenges and opportunities. Enter Cipla with its expertise in medicine, and vision for relevance beyond pharma.
